Oruka Therapeutics, Inc. (ORKA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$92.51+1.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ORKA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ORKA — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, Oruka Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other…
Why it matters: This event shows Oruka is expanding its pipeline to new treatment areas.
Supportive ifORKA-004 enters clinical trials as planned in Q4 2026.
Worry ifORKA-004's clinical entry is delayed beyond Q4 2026.
Why it matters: If healthcare revenue growth speeds up, it could help Oruka's performance. This is important as the sector is currently slowing.
Supportive ifHealthcare sector revenue growth rises back toward 10% or higher.
Worry ifHealthcare sector revenue growth continues to slow below 10%.
Why it matters: The trial results will show if ORKA-001 is effective for psoriasis. Positive results could boost investor confidence.
Supportive ifThe trial meets its primary endpoint of PASI 100 response in patients.
Worry ifThe trial fails to meet its primary endpoint or shows no significant improvement.
Why it matters: High cash burn rates can limit future funding options. This is critical for ongoing operations.
Worry ifCash from operations remains negative and worsens from -$23.6M in Q1 2026.
Less concerning ifCash from operations improves and turns positive in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $609 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,799 loss on $10,000 · 28.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Positive results could boost confidence in ORKA-001 for treating psoriasis. This is key to growth.
Supportive ifThe trial shows a big increase in PASI 100 scores. This is better than placebo.
Worry ifThe trial fails to meet its primary endpoint or shows no significant improvement.
Why it matters: This data will show how well ORKA-002 works for psoriasis. Good results could increase the drug's market value.
Supportive ifWeek 16 data shows at least 50% of participants achieving HiSCR75.
Worry ifLess than 40% of participants achieve HiSCR75 at Week 16.
Why it matters: Updates will show how ORKA-001 is developing. Good news could boost investor trust.
Supportive ifPositive interim results reported for the Phase 2b trial in 2027.
Worry ifNo updates or negative results reported for the Phase 2b trial in 2027.
Why it matters: This data will show how well ORKA-001 maintains its effectiveness over six months.
Supportive ifWeek 28 data shows at least 60% of participants maintaining PASI 100.
Worry ifLess than 50% of participants maintain PASI 100 at Week 28.
Why it matters: This data will help determine the path to a Phase 3 trial for ORKA-001.
Supportive ifWeek 16 data shows good results. This supports starting Phase 3.
Worry ifWeek 16 data shows poor efficacy results, delaying Phase 3 plans.
Why it matters: This data helps us understand how well ORKA-002 treats psoriasis.
Supportive ifWeek 16 data shows big improvements in psoriasis symptoms for ORKA-002.
Worry ifWeek 16 data shows no big changes in psoriasis symptoms.